Short answer
Krystal Biotech, Inc. (KRYS) filed an 8-K current report with the SEC on August 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 financial results announced for quarter ended June 30, 2026.
Krystal Biotech, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 financial results announced for quarter ended June 30, 2026
- Press release containing results attached as Exhibit 99.1
- Results furnished under Item 2.02, limiting Exchange Act Section 18 liability and automatic incorporation into filings
Item EX-99.1 · Exhibit EX-99.1
- 2Q revenue $119.2M, up 24% year over year, with 95% gross margin and $54.8M net income
- VYJUVEK cumulative revenue reached $965.9M, supporting continued commercial-funding capacity
- Cash and investments totaled $1.1B, providing substantial runway for pipeline expansion and international launches
- Italy and Spain launches targeted before year-end, while Germany and France reimbursement negotiations remain ongoing
- Multiple potential catalysts in 2H 2026, including KB803 data, KB407 interim results, KB111 results, and Gorlin syndrome updates
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Krystal Biotech, Inc. 8-K filings
Get the next KRYS 8-K as it lands
Follow KRYS for push alerts, or ask the research agent what this filing means.